

Appointment of New Non-Executive Director

✓ **Sue MacLeman joins the Board as a Non-Executive Director.**

31 January 2023, Melbourne: Transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) is pleased to announce the appointment of one of the more experienced and respected leaders in Australia's MedTech industry, Ms Sue MacLeman as an independent, Non-Executive Director, effective immediately.

About...

Sue MacLeman BPharm, LLM, MMkt, FAICD, FATSE, FACPP

Sue has more than 30 years' experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development at Schering-Plough Corporation (now Merck), Amgen, Bristol-Myers Squibb and Mesoblast. Sue has also served as CEO and a Board member of several ASX, AIM and NASDAQ listed companies in the Healthtech sector.

Sue is currently the Chair of the Medical Technologies and Pharmaceuticals Growth Centre (MTPConnect). Sue is a Non Executive Director of Planet Innovation Holdings Ltd, ATSE and OMICO (Australian Genomic Cancer Medicines Ltd). Sue is also a member of the NSW Innovation and Productivity Council, Fellow of the Australian Academy of Technology and Engineering (ATSE) and Fellow/Graduate of Australian Institute of Company Directors (AICD). Sue is also appointed to several academic and government advisory boards.

Sue brings a unique set of experiences in technology commercialisation, strategic planning, capital markets and fund raising, M&A and alliance management. Her broad commercial and technical experience is underpinned by a Bachelor of Pharmacy from the University of Queensland, a Master of Laws from Deakin University and a Master of Marketing from Melbourne Business School.

Rhythm Executive Chairman, Mr Otto Buttula, commented:

"We are delighted that Sue accepted the invitation to join the Board of Rhythm and believe she is an excellent addition to the Company's Board. Sue's significant range of different qualifications and real-world experiences, incorporating commercial, both domestically and overseas, in addition to working with various government initiatives and taskforces should be a strong asset to the Company as we look to close on several commercial activities. Further, Sue's many connections to key stakeholders in the Healthtech ecosystem globally should provide valuable insights to help guide the business during the strong growth period that we expect to have ahead of us."

Incoming Non-Executive Director, Ms Sue MacLeman, commented:

"I am delighted to join the board of Rhythm having followed the company since its inception. I have been interested in improving public health for my whole career and have keenly followed the advancements and milestones achieved by Rhythm in recent times."

Directors

Otto Buttula
Glenn Gilbert
Trevor Lockett
Rachel David
Louis Panaccio
Sue MacLeman

Executive Chairman
Managing Director
Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director

“The Company has the potential to transform the way colorectal cancer is detected and potentially on an international scale. I am looking forward to working with the team as the Company moves to commercialisation and realise the potential for this Australian developed technology. That, in addition to developing other simple, but transformative diagnostics products is something I am excited to be a part of and I am looking forward to using my skills and expertise to assist Rhythm as they scale globally.”

- ENDS -

Authorised for release by the Board.

For further information contact:

Glenn Gilbert
CEO and Managing Director
+61 3 8256 2880

About Rhythm Biosciences

Rhythm Biosciences is focused on becoming a globally significant, transformative, predictive diagnostics company, specialising in cancer detection technology. The Company is currently developing ColoSTAT® - a simple, low-cost, blood test for global mass market detection of colorectal cancer.

Worldwide, colorectal cancer is the third most common cancer in men and the second most common in women, accounting for an estimated 1.9 million new cases and 935,000 deaths annually.

In an effort to reduce the global burden, many countries have implemented screening programs aimed at early detection. These programs are predominantly administered with a faecal immunochemical test (FIT) for the assessment of colorectal cancer risk, with a positive result referred for a colonoscopy. FIT only analyses the presence of blood in faeces, which can occur for several reasons other than cancer, therefore it is not designed as an accurate test for cancer. Many people simply don't take the test for fear of an unnecessary colonoscopy procedure, unpleasantness, difficulty, or for religious/cultural reasons. There is currently no appropriate blood test alternative.

Rhythm aims to transform the global mass-market for colorectal cancer detection with ColoSTAT® its simple, low-cost blood test that is fit for purpose, meaning that it is designed to actually detect colorectal cancer. Since listing on the ASX in 2017, the Company has run a successful multi-year research and development program that has delivered technical validation of the core biomarker technology, being reproducible and stable. The ColoSTAT® test-kit was manufactured in 2021 and delivered performance testing that outperforms the current market standard faecal immunochemical test utilising Rhythm's proprietary algorithm. The Company is progressing regulatory, manufacturing and scale up activities ahead of market entry in FY23.

ColoSTAT® is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT® has the potential to play a key role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Rhythm's initial targeted global addressable population is over 800 million people which are over 50 years of age. Almost 70%, or 550 million people, are not currently screened for colorectal cancer due to the limitations of the current faecal based testing regime. This “at risk” population is also expanding with the disease growing rapidly in much younger age groups. Early detection and intervention can lead to cure in over 90 per cent of new cases, therefore the need for effective screening and early intervention has the potential to save a significant number of lives. Rhythm estimates today's colorectal cancer screening market alone to be worth in excess of \$38 billion.